Projects per year
Abstract
Arsenic is a clinically effective treatment for acute promyelocytic leukaemia (APL) in which the promyelocytic leukaemia (PML) protein is fused to retinoic receptor alpha (RARa). PML-RARa is degraded by the proteasome by a SUMO-dependent, ubiquitin-mediated pathway in response to arsenic treatment, curing the disease. Six major PML isoforms are expressed as a result of alternative splicing, each of which encodes a unique C-terminal region. Using a system in which only a single EYFP-linked PML isoform is expressed, we demonstrate that PMLI, PMLII and PMLVI accumulate in the cytoplasm following arsenic treatment, whereas PMLIII, PMLIV and PMLV do not. 3D structured illumination was used to obtain super-resolution images of PML bodies, revealing spherical shells of PML along with associated SUMO. Arsenic treatment results in dramatic isoform-specific changes to PML body ultrastructure. After extended arsenic treatment most PML isoforms are degraded, leaving SUMO at the core of the nuclear bodies. A high-content imaging assay identifies PMLV as the isoform most readily degraded following arsenic treatment, and PMLIV as relatively resistant to degradation. Immunoprecipitation analysis demonstrates that all PML isoforms are modified by SUMO and ubiquitin after arsenic treatment, and by using siRNA, we demonstrate that arsenic-induced degradation of all PML isoforms is dependent on the ubiquitin E3 ligase RNF4. Intriguingly, depletion of RNF4 results in marked accumulation of PMLV, suggesting that this isoform is an optimal substrate for RNF4. Thus the variable C-terminal domain influences the rate and location of degradation of PML isoforms following arsenic treatment.
Original language | English |
---|---|
Pages (from-to) | 365-375 |
Number of pages | 11 |
Journal | Journal of Cell Science |
Volume | 127 |
Issue number | 2 |
DOIs | |
Publication status | Published - 15 Jan 2014 |
Fingerprint
Dive into the research topics of 'PML isoforms in response to arsenic: high-resolution analysis of PML body structure and degradation'. Together they form a unique fingerprint.Projects
- 3 Finished
-
Strategic Award: Wellcome Trust Technology Platform
Blow, J. (Investigator), Lamond, A. (Investigator) & Owen-Hughes, T. (Investigator)
1/01/13 → 30/09/18
Project: Research
-
Dynamics of Fundamental Cellular Processes by Live Cell and Tissue Imaging
MacDonald, M. (Investigator), McGloin, D. (Investigator), McKenna, S. (Investigator), Storey, K. (Investigator), Swedlow, J. (Investigator) & Weijer, K. (Investigator)
1/01/13 → 31/12/17
Project: Research
-
Determining the Role and Mechanism of Action of SUMO Targeted Ubiquitin Ligase RNF4 in Maintaining Genome Integrity (Senior Investigator Award)
Hay, R. (Investigator)
1/10/12 → 31/01/20
Project: Research